
Chaperonin 10: Short term relief for rheumatoid arthritis patients

Chaperonin 10: Short term relief for rheumatoid arthritis patients
Therapeutic efficacy and safety of chaperonin 10 in patients with rheumatoid arthritis: a double-blind randomised trial
Lancet. 2006 Dec 2;368(9551):1964.Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
23 patients with moderate to severe active rheumatoid arthritis were randomized to receive either 5 mg, 7.5 mg, or 10 mg of Chaperonin 10, an anti-inflammatory drug, intravenously twice weekly for 12 weeks. Disease activity score and core disease measures were assessed throughout the course of the study. By the end of the 12 week study, it was determined that improvement in rheumatoid arthritis wa...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!

Learn about our AI Driven
High Impact Search Feature

Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.